Benzinga | Oct 6, 2020 08:01AM EDT

Biocept Says Has Received Mored Than 50,000 COVID-19 Specimens To Date

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory.

"We have continued to gain momentum in testing COVID-19 specimens while maintaining a standard of providing the vast majority of COVID-19 test results to our healthcare provider customers within 48 hours of receiving a sample," said Michael Nall, President and CEO of Biocept. "I am proud of our team for working hard to scale our business in a short time to handle this rapidly increasing volume."

Biocept's growing list of clients for COVID-19 testing includes hospitals, clinics, skilled nursing facilities, corporate clients and athletic facilities.

Biocept is also reporting progress with its internally developed COVID-19 specimen collection kits. The Company has received verification from a contract research organization (CRO) of the viricidal effects of the specimen collection tube used for shipping patient samples. This was an important gating factor prior to the adoption of the internally developed kits. The Biocept-developed COVID-19 specimen collection kit will now be validated as part of the Company's COVID-19 workflow in the Company's lab prior to being sent to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EAU) review. Biocept remains on track for launching the Biocept-developed specimen collection kits later this year for use in its lab and for potential sales to other labs.